About
Technology
Issues
FAQ
Links
Official Page
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.